Ideas Discussions Themes Map Live Ask AI

All beneficiaries

organization

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Information regarding this entity could not be verified from the provided research brief.

Ideas that could help Dana-Farber Cancer Institute

Hallmark Co-Targeting Combination DesignerWhy it helps: Its molecular tumor boards handle complex, heavily pretreated cases where single-agent options are exhausted; a framework-ranked combination shortlist gives a defensible basis for off-label and trial selections.
Cancer Fatigue Pathway PanelWhy it helps: Its survivorship clinic and Zakim Center for integrative care already pair exercise referrals with integrative outcomes; a pathway-stratified panel adds a measurable endpoint to that model.
RareCohort Prognosis Kit: Few-Shot Survival Models from Small Slide ArchivesWhy it helps: Hosts rare-tumor programs and large slide archives; the service converts archived cohorts into validated prognostic models for research and protocol design without an internal ML team per cancer type.
24-Hour IFN Priming Check After mRNA VaccinationWhy it helps: Its immuno-oncology clinical trials group can use the assay as a pharmacodynamic biomarker to stratify and interpret vaccine-ICI combination protocols.
Spatial Assay Distiller: 18,000-Gene Discovery to 60-Marker Clinical PanelWhy it helps: Its translational research groups produce high-plex spatial datasets tied to outcomes; the service converts those datasets into standardized assays usable in its own clinical trials instead of leaving them as research artifacts.
Combo-vs-Mono Decision Aid for First-Line EGFR-Mutated NSCLCWhy it helps: Academic cancer center with a large thoracic oncology service and shared decision-making programs; it could pilot the aid, lend credibility, and standardize the regimen conversation across its network.
Pre-Treatment Tumor Potency-State Report for Immunotherapy StratificationWhy it helps: Its combined single-cell and immuno-oncology research programs would use a standardized potency-state profile to compare responder versus non-responder tumors prospectively.

Recent research, turned into concrete, commercially plausible innovation ideas — each with an interactive prototype you can try.

Explore

Ideas
Discussions
Themes
Live
Research
Map
Personas
Who benefits
Ask AI

For you

For researchers
For industry
For investors

Learn more

About
How it works
FAQ

Account

Sign in
Your space
Your stream
Your digest
Your contexts
Your data

© 2026 SeedlabsRecent research, turned into shippable ideas.